Study author Steven R. Messé, MD, of the University of Pennsylvania in Philadelphia and a Fellow of the American Academy of Neurology said, “Even though the clot-busting treatment for stroke called tPA improves recovery, some people who are eligible to receive the treatment are not getting it. We wanted to find out what factors were associated with lower likelihood of treatment, which may help us find ways to improve tPA use in the future.”
The study was a meta-analysis, where the team combined through thousands of pages of data. The hospital records of patients who arrived at the emergency department within two hours of the onset of stroke symptoms and were eligible for the drug, with no contraindications, were analyzed during an 8 year period from 2003 to 2011. In total, the team looked at 61,698 ischemic stroke patients.
After taking into account confounding factors including stroke severity, the researchers found that women and minorities were less likely to receive treatment. Of the records examined, 50.6% were from women, but female patients had an 8% higher chance of not receiving life-saving tPA treatment compared to men. African American patients were especially at risk, having 26% higher chance of missing out on tPA therapy compared to white patients. These two groups of patients combined made up over half of the patients included in the study and yet they were at a significantly higher risk of being under-treated.
It did matter where treatment was received. Patients treated at hospitals that were certified as stroke centers were much more likely to receive the gold standard of tPA treatment. Patients who were treated at hospitals that were not certified as stroke centers were half as likely to receive the clot busting drugs. The study was supported in part by Pfizer, Inc., and the Merck-Schering Plough Partnership. The video below talks about the symptoms of stroke and the impact they can have on the body, make sure you know the signs.
Sources: American Academy of Neurology , National Stroke Association, Perelman School of Medicine UPenn, Journal Neurology